Company: MIRA
Filing Date: 2025-07-29
Form Type: PRER14A
Source: 0001641172-25-021434
Chunk: 175

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-07-29
Form: PRER14A
Chunk 175
---
 therewith): (a)any obligations of such Person for borrowed money or in respect of loans or advances (whether or not evidenced by bonds, debentures, notes, or other similar instruments or debt securities); (b)any obligations of such Person as lessee under any lease or similar arrangement required to be recorded as a capital lease in accordance with GAAP; (c)all liabilities of such Person under or in connection with letters of credit or bankers’ acceptances, performance bonds, sureties or similar obligations; (d)any obligations of such Person to pay the deferred purchase price of property, goods or services other than those trade payables incurred in the ordinary course of business; (e)all liabilities of such Person arising from cash/book overdrafts; (f)all liabilities of such Person under conditional sale or other title retention agreements; (g)all liabilities of such Person arising out of interest rate and currency swap arrangements and any other arrangements designed to provide protection against fluctuations in interest or currency rates; (h)any liability or obligation of others guaranteed by, or secured by any Lien on the assets of, such Person; (i)with respect to the Company, the net amount of any obligation or liability of the Company to the Company or any Affiliate thereof (excluding all employment or consulting compensation, employee benefits or expense reimbursement payable to any Affiliate in accordance with the Company’s existing policies and procedures); and (k)all unpaid Taxes (whether or not due and payable) as of the Closing Date;

| 41 |

8.9.28 “ Intellectual Property” means: (a)trademarks and service marks (whether registered or unregistered), trade names, designs and general intangibles of like nature, together with all goodwill related to the foregoing (collectively, “ Trademarks”); (b)patents (including any continuations, continuations in part, renewals, extensions and applications for any of the foregoing) (collectively, “ Patents”); (c)copyrights (including any registrations and applications therefor and whether registered or unregistered) (collectively, “ Copyrights”); (d)computer software; databases; works of authorship; mask works; technology; trade secrets and other confidential information, know-how, proprietary processes, formulae, algorithms, models, user interfaces, customer lists, inventions, discoveries, concepts, ideas, techniques, methods, source codes, object codes, methodologies; and (e)with respect to all of the foregoing, related confidential data